Works about PROPROTEIN convertases

Results: 377
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12

    Alirocumab vs usual lipid‐lowering care as add‐on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM‐DYSLIPIDEMIA randomized trial.

    Published in:
    Diabetes, Obesity & Metabolism, 2018, v. 20, n. 6, p. 1479, doi. 10.1111/dom.13257
    By:
    • Ray, Kausik K.;
    • Letierce, Alexia;
    • Samuel, Rita;
    • Del Prato, Stefano;
    • Leiter, Lawrence A.;
    • Müller‐Wieland, Dirk;
    • Cariou, Bertrand;
    • Colhoun, Helen M.;
    • Henry, Robert R.;
    • Tinahones, Francisco J.;
    • Bujas‐Bobanovic, Maja;
    • Domenger, Catherine
    Publication type:
    Article
    13
    14

    Plasma proprotein‐convertase‐subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes.

    Published in:
    Diabetes, Obesity & Metabolism, 2018, v. 20, n. 4, p. 943, doi. 10.1111/dom.13181
    By:
    • El Khoury, Petra;
    • Abou‐Khalil, Yara;
    • Abifadel, Marianne;
    • Ghaleb, Youmna;
    • Elbitar, Sandy;
    • Jacob, Marie‐Paule;
    • Andreata, Francesco;
    • Caligiuri, Giusepinna;
    • Varret, Mathilde;
    • Boileau, Catherine;
    • Steg, Philippe Gabriel;
    • Roussel, Ronan;
    • Potier, Louis;
    • Marre, Michel;
    • Hansel, Boris;
    • Mohammedi, Kamel;
    • Fumeron, Frederic;
    • Velho, Gilberto;
    • Ragot, Stephanie;
    • Hadjadj, Samy
    Publication type:
    Article
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36

    The effects of single‐ and multiple‐dose administration of bococizumab (RN316/PF‐04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies

    Published in:
    Cardiovascular Therapeutics, 2018, v. 36, n. 1, p. 1, doi. 10.1111/1755-5922.12309
    By:
    • Gumbiner, Barry;
    • Joh, Tenshang;
    • Liang, Hong;
    • Wan, Hong;
    • Levisetti, Matteo;
    • Vana, Alicia M.;
    • Shelton, David L.;
    • Forgues, Philippe;
    • Billotte, Stephan;
    • Pons, Jaume;
    • Baum, Charles M.;
    • Garzone, Pamela D.
    Publication type:
    Article
    37
    38
    39
    40
    41
    42
    43

    PCSK9 inhibition with alirocumab reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein(a) production rate.

    Published in:
    Clinical Science, 2018, v. 132, n. 10, p. 1075, doi. 10.1042/CS20180040
    By:
    • Croyal, Mikaël;
    • Thi-Thu-Trang Tran;
    • Blanchard, Rose Hélène;
    • Le Bail, Jean-Christophe;
    • Villard, Elise F.;
    • Poirier, Bruno;
    • Aguesse, Audrey;
    • Billon-Crossouard, Stéphanie;
    • Ramin-Mangata, Stéphane;
    • Blanchard, Valentin;
    • Nativel, Brice;
    • Chemello, Kévin;
    • Khantalin, Ilya;
    • Thedrez, Aurélie;
    • Janiak, Philip;
    • Krempf, Michel;
    • Boixel, Christophe;
    • Lambert, Gilles;
    • Guillot, Etienne
    Publication type:
    Article
    44

    The complexity of lipoprotein (a) lowering by PCSK9 monoclonal antibodies.

    Published in:
    Clinical Science, 2017, v. 131, n. 4, p. 261, doi. 10.1042/CS20160403
    By:
    • Lambert, Gilles;
    • Thedrez, Aurélie;
    • Croyal, Mikaël;
    • Ramin-Mangata, Stéphane;
    • Couret, David;
    • Diotel, Nicolas;
    • Nobécourt-Dupuy, Estelle;
    • Krempf, Michel;
    • LeBail, Jean Christophe;
    • Poirier, Bruno;
    • Blankenstein, Jorg;
    • Villard, Elise F.;
    • Guillot, Etienne
    Publication type:
    Article
    45
    46
    47
    48
    49
    50